IMGN Financial Facts

Clinical materials reimbursement: 125K
Research and development: 20.86M
See Full Income Statement

Accrued compensation: 4.16M
Total liabilities: 72.49M
See Full Balance Sheet

Immunogen Inc. (IMGN) Earnings

  |   Expand Research on IMGN
Next EPS Date 4/29/14 *Est. EPS Growth Rate +113.8% *Last Qtr.
Average EPS % Beat Rate +66.4% Revenue Growth Rate +1,057.7% *Last Qtr.
Average % Move 1-Wk after EPS -4.7% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. % Since Details
1/31/14 Q214 $0.04-$0.18 +$0.22$30.1M$18.16M = -7.2% Details
10/25/13 Q114 -$0.13-$0.23 +$0.10$17.2M$12.1M = -18.9% Details
8/2/13 Q413 -$0.26-$0.30 +$0.04$3.83M$3.44M = -27.8% Details
4/26/13 Q313 -$0.02-$0.15 +$0.13$25M$11.94M N/A -6.9% Details
1/25/13 Q213 -$0.29-$0.25 -$0.04$2.6M$6.02M N/A -8.9% Details
10/26/12 Q113 -$0.30-$0.25 -$0.05$4.1M$4.1M N/A +1.5% Details
8/3/12 Q412 -$0.29-$0.30 +$0.01$2.95M$3.26M N/A -9.2% Details
4/27/12 Q312 -$0.24-$0.25 +$0.01$3.25M$4.24M N/A +10.3% Details